Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Rodman & Renshaw Reiterates Market Outperform and PT of $10 on SciClone Pharmaceuticals

Emily Austin, Benzinga Staff Writer
August 12, 2011 9:04 AM
+ Follow
Print
Email
Tickers: SCLN
Benzinga Share:

Rodman & Renshaw reiterated its Market Outperform rating on SciClone Pharmaceuticals (NASDAQ: SCLN). At the same time, the rating agency left its price target on the company's stock unchanged at $10. On Thursday, SCLN closed the day at $5.07.

(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Tags: Rodman and Renshaw

Posted in: Reiteration, Analyst Ratings

 

Around the Web, We're Loving...

Rev. Michael Reilly: NY Marathon Only Making Matters Worse in City
Oil, Gasoline Pounded; East Coast Supplies Eyed
A Microsoft Smartphone? After Surface Tablet, It Might Just Happen
Jobs Rose 171,000 In October; Unemployment Rate 7.9%
McDonald's No Longer Overcooked

Most Popular

Study: Amazon is Nibbling Netflix's Lunch
Benzinga's Microcap Movers for Thursday November 1, 2012
UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Starbucks Corporation
iPad Mini Launch Brings Small Crowd, Few iPad 4 Buyers
Earnings Scheduled For November 2, 2012
UPDATE: Jefferies & Company Downgrades Exelon Corporation to Hold, Lowers PT

Related Articles (SCLN)

Partner Network

Posts by Emily Austin

Benzinga Professional

Subscribe

Benzinga's News Delivered Free

Brain Trust

See All Brain Trust Columnists